Ozempic side effects and diabetes shortages: sorting fact from fear

What did @user42058832 actually say?

Here's the honest answer: the transcript is almost entirely song lyrics, not spoken claims. The actual medical content lives in the caption, where the creator describes months of nausea and vomiting, mentions "pancreatic" concerns, describes searching a 100-mile radius for Ozempic during the weight-loss shortage, and concludes: "NOT A FAN WOULD NOT ADVOCATE FOR IT... everyone is different and their bodies re[act differently]."

That's the real substance here. A person with diabetes sharing a rough personal experience with semaglutide (Ozempic), frustrated by both the drug's side effects and by supply disruptions caused by off-label demand. The song is background. The caption is the claim.

Does the science back this up?

On the side effects? Yes, largely. On the shortage? Completely. On the implied pancreatic risk? More complicated.

Nausea and vomiting are the most common adverse effects of semaglutide, affecting roughly 15 to 44 percent of patients in clinical trials depending on dose and titration speed (Davies et al., 2021, Diabetes Care). These are not rare edge cases. They're expected, especially early in treatment. The creator's experience is well within what the clinical literature predicts.

The Ozempic shortage was real and documented. The FDA placed semaglutide on its drug shortage list starting in 2022, directly attributing the disruption to demand driven by weight management use, which left patients with type 2 diabetes competing for supply (FDA Drug Shortage Database, 2022-2023). This person wasn't imagining it.

The word "pancreatic" in the caption is less clear-cut and worth addressing directly below.

What did they get wrong (or right)?

The creator gets significant credit for the core experience. The side effect profile they describe is clinically accurate, and their observation that "everyone is different and their bodies re[act]" reflects something genuinely supported by data. Gastrointestinal tolerability varies widely between patients, and individual discontinuation is a legitimate outcome (Wilding et al., 2021, NEJM).

The pancreatic mention is the one area that needs scrutiny. The caption is ambiguous, but if the creator is implying semaglutide caused pancreatic damage, the current evidence doesn't support a clear causal link. Post-marketing surveillance has identified rare reports of pancreatitis, but major studies including the SUSTAIN trials found no statistically significant increase in pancreatitis risk versus placebo (Marso et al., 2016, NEJM). The FDA label does carry a warning, but "pancreatic" concerns should not be stated or implied as established harms without qualification.

What they got right: the shortage was real, the side effects were real, and individual responses to GLP-1 drugs do vary substantially. That's not a minor point. Too much online content about Ozempic ignores these realities entirely.

What should you actually know?

A few things this video, read carefully, points toward that are worth knowing.

• GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) carry a well-documented gastrointestinal side effect burden. The standard clinical guidance is to titrate slowly to reduce nausea, but even with proper titration, a meaningful percentage of patients discontinue due to intolerance.
• The 2022-2023 Ozempic shortage was a documented public health problem. People with type 2 diabetes, for whom semaglutide is an approved first-line treatment, faced real access disruptions because of demand from people using it for weight loss. This is not a hypothetical equity concern.
• Pancreatitis risk with GLP-1 drugs is listed as a precaution but has not been confirmed as a definitive causal risk in large randomized trials. Patients with a personal or family history of pancreatitis are typically advised to use caution or avoid this drug class.
• Individual variability in GLP-1 tolerability is real. A bad experience with semaglutide does not mean all GLP-1 drugs will produce the same outcome. Tirzepatide (Mounjaro, Zepbound) and liraglutide (Victoza) have different pharmacological profiles and different side effect distributions.
• No one should stop or switch a diabetes medication based on a TikTok video, including this one. The creator explicitly is not advocating for anyone else, which is the right call.

The bottom line

This is a patient sharing a difficult personal experience with a real medication that caused real side effects during a real supply shortage. The core claims in the caption are accurate or at least well-grounded in clinical data. The pancreatic language is the one piece that deserves more precision than a caption allows. The creator is not making reckless health claims. They're saying the drug was hard on their body and the supply situation made their diabetes management harder. Both of those things are true for a lot of people, and that's worth acknowledging.